Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H1 2018

June 2018 | 37 pages | ID: G4ACBC9E19AEN
Global Markets Direct

Abstracts

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H1 2018'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. It mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H1 2018' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Genetic Disorders which include indications Autism, Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Down Syndrome, Ischemic Cerebral Stroke, Mild Cognitive Impairment, Pervasive Developmental Disorder (PDD), Schizophrenia and Traumatic Brain Injury.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)
• The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
• The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Companies Involved in Therapeutics Development
AgeneBio Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ono Pharmaceutical Co Ltd
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Drug Profiles
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basmisanil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8590580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7816 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-4938581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7017773 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-44819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABRA5 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonise GABRA5 for Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GABRA5 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Product Development Milestones
Featured News & Press Releases
Sep 13, 2017: AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer’s Disease
Jun 30, 2017: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for Drug-Discovery Program to Delay the Onset of Alzheimer’s Dementia
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AgeneBio Inc, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Les Laboratoires Servier SAS, H1 2018
Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

AgeneBio Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ono Pharmaceutical Co Ltd